Natriuretic peptides and the genomics of left-ventricular hypertrophy.
Left-ventricular hypertrophy (LVH) is one of the strongest independent predictors of cardiovascular morbidity and mortality in the general population. Although hypertension and obesity are well-established, independent risk factors for the development of LVH, they explain less than 25% to 50% of the variance of left ventricular mass (LVM) in humans. A substantial body of evidence suggests that there is a genetic basis to the observed inter-individual variability in the susceptibility to the development of LVH. Given the continuous relationship between LVM and cardiovascular morbidity and mortality, elucidating the genetic determinants of inter-individual differences in the susceptibility to LVH is of considerable public health importance. It promises the opportunity to identify high-risk individuals for targeted intervention and may identify novel therapeutic targets for improved prevention and treatment strategies.
Dries
Daniel L
DL
Penn Cardiovascular Institute and Cardiovascular Division, Heart Failure and Transplant Group, Heart Vascular Center, 3400 Civic Center Boulevard, Philadelphia, PA 19104-4283, USA. daniel.dries@uphs.upenn.edu
D001741:Black or African American / Q000235:genetics; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000235:genetics / Q000401:mortality; D014644:Genetic Variation; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D017379:Hypertrophy, Left Ventricular / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics* / Q000401:mortality; D045265:Natriuretic Peptides / Q000235:genetics* / Q000502:physiology; D018570:Risk Assessment; D012697:Serine Endopeptidases / Q000235:genetics; D014481:United States / Q000453:epidemiology
D000959:Antihypertensive Agents; D045265:Natriuretic Peptides; C119812:CORIN protein, human; D012697:Serine Endopeptidases